Dostarlimab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dostarlimab: From Endometrial Cancer to Tendinopathy
One-Sentence Summary
Dostarlimab (Jemperli) is a humanised monoclonal antibody targeting the PD-1 checkpoint receptor, approved in multiple markets for mismatch repair-deficient (dMMR) / microsatellite instability-high (MSI-H) endometrial cancer and other solid tumours. The TxGNN model ranks tendinopathy as its top predicted new indication, with a prediction score of 50.00% and a model rank of #51,903 — placing it near the bottom of all candidate diseases. There are currently 0 clinical trials and 0 publications supporting this direction, and the mechanistic rationale is not only absent but actively contradictory.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mismatch repair-deficient (dMMR) / MSI-H endometrial cancer; dMMR/MSI-H recurrent or advanced solid tumours |
| Predicted New Indication (Rank 1) | Tendinopathy |
| TxGNN Prediction Score | 50.00% (Model Rank #51,903) |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacological information, Dostarlimab is a PD-1 (programmed cell death protein 1) checkpoint inhibitor. It works by blocking the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) expressed on tumour cells, thereby releasing the immune "brake" and restoring anti-tumour T cell activity. This mechanism of immune activation is the cornerstone of its efficacy in dMMR/MSI-H cancers, which are immunologically "hot" tumours with high neoantigen burden.
Tendinopathy is a degenerative or overuse-related structural injury to tendons, with a variable inflammatory component. Importantly, the inflammatory component in tendinopathy — where it exists — is characterised by local tissue remodelling rather than adaptive immune suppression. Releasing PD-1-mediated immune brakes provides no mechanistic pathway to promote tendon healing or reduce degenerative collagen remodelling.
The mechanistic link is not merely absent — it may be harmful. Checkpoint inhibitor-related musculoskeletal immune-related adverse events (irAEs), including inflammatory arthritis and tendinitis, are already well-documented clinical phenomena. This means Dostarlimab's immune-activating mechanism could theoretically worsen tendon inflammation rather than treat it. The high model rank (#51,903) and borderline score (50.00%) suggest this is most likely a knowledge graph artefact rather than a biologically grounded prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Dostarlimab has no registered products in Singapore at this time. The drug is therefore not available through local regulatory channels for any indication.
Cytotoxicity
Dostarlimab is an antineoplastic agent (PD-1 immune checkpoint inhibitor). The following summary applies:
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted immunotherapy — Checkpoint inhibitor (anti-PD-1 monoclonal antibody); NOT conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Low (not a direct myelosuppressive agent; immune-related cytopenias are uncommon but reported as irAEs) |
| Emetogenicity Classification | Minimal (intravenous biological, not classified as emetogenic per MASCC/ESMO guidelines) |
| Monitoring Items | Thyroid function (TSH/free T4), liver enzymes (ALT/AST), renal function (creatinine), blood glucose, full blood count, adrenal function as clinically indicated; monitor for irAEs at each infusion cycle |
| Handling Protection | Biological/monoclonal antibody — standard aseptic preparation required; conventional cytotoxic handling precautions are not mandated, but institutional biohazard protocols for large-volume IV preparations apply |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 TxGNN-predicted indications for Dostarlimab carry L5 evidence (model prediction only, zero supporting clinical trials or publications), and critically, the mechanistic direction of a PD-1 immune activator is contraindicated or irrelevant for every predicted disease — including tendinopathy, autoimmune retinopathy, anaphylaxis variants, metabolic disorders, and epilepsy syndromes. The top prediction rank of #51,903 further confirms that the model did not generate confident candidates; these predictions are near the floor of the ranked output and are most likely knowledge graph false-positive connections.
To proceed, the following is needed:
- Mechanistic alignment review: Any future repurposing screen for Dostarlimab should focus on immune-suppressed or tumour-immune-evasion contexts (e.g., autoimmune-associated malignancies, viral oncogenesis), not conditions where immune activation is harmful or irrelevant
- MOA documentation: Obtain formal DrugBank MOA record to populate the mechanism field and enable proper mechanistic filtering in the prediction pipeline
- Singapore regulatory pathway: Since the drug is not registered in Singapore, any indication expansion would require full HSA registration or a clinical trial import authorisation (CTA)
- Model calibration signal: The uniform score of 0.5 across all 10 predicted indications suggests a possible scoring artefact or edge-case in the TxGNN pipeline for this drug — flagging for model team review is recommended
- irAE risk profile documentation: Before any exploratory use outside oncology, a comprehensive irAE (immune-related adverse event) risk assessment should be completed, given that many predicted disease contexts (autoimmune conditions, allergic conditions) represent active contraindications for PD-1 inhibitor use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.